Comparison of two models for predicting non-sentinel lymph node metastases in sentinel lymph node-positive breast cancer patients.

Several models for the prediction of non-sentinel lymph node (SLN) metastasis in SLN-positive breast cancer patients have been proposed. In this study, the authors evaluate the Memorial Sloan-Kettering Cancer Center (MSKCC) nomogram and an axilla scoring system from Tenon Hospital to predict the probability of having non-(SLN) involvement and to define their actual usefulness when applied to the subgroup of patients with micrometastasis in SLN. The study population consisted of 103 patients: 74 with macrometastasis and 29 with micrometastasis in the SLN.

Sentinel lymph node micrometastasis and risk of non-sentinel lymph node metastasis: validation of two breast cancer nomograms.

Introduction: The aim of this study is to validate the predictive value of the Memorial Sloan-Kettering Cancer Center (MSKCC) nomogram and the Tenon score system in our sentinel lymph node (SLN)-positive series, and to define their actual usefulness when applied to the subgroup of patients with micrometastasis in SLN.

Patients And Methods: The study population consisted of 95 patients: 68 with macrometastasis and 27 with micrometastasis in the SLN. The predicted probability of non-SLN metastasis was calculated for each patient by using a computerized model from the MSKCC Web site.

Familial and sporadic breast cancers: differences in clinical, histopathological, and immunohistochemical features.

In the present study, the authors investigated the clinical, histopathological, and immunohistochemical features in familial breast cancer (FBC) patients and compared them with findings in sporadic breast cancers (SBCs); hormone receptor status was stratified by age. A total of 849 patients treated for breast cancer were included in the study. The patients were stratified into 2 groups: FBC, 160 patients (19%), and SBC, 689 patients (81%).

Sentinel lymph node biopsy in patients with pure and high-risk ductal carcinoma in situ of the breast.

Aims And Background: The role of sentinel lymph node biopsy in patients initially diagnosed with ductal carcinoma in situ resides in determining the predictors of invasive disease. The aim of the present study was to examine the incidence of sentinel lymph node metastases in a selected group of patients, with characteristics of high-risk ductal carcinoma in situ, in order to determine the clinical usefulness of sentinel lymph node biopsy.

Methods: A total of 90 patients with a biopsy diagnosis of ductal carcinoma in situ were treated.

Sentinel lymph node biopsy in multiple breast cancer using subareolar injection of the tracer.

We performed subdermal injection of (99m)Tc-labelled albumin combined with subareolar (SA) injection of blue dye to axillary lymphatic mapping and sentinel lymph node biopsy (SLNB) in patients with multifocal and multicentric breast cancer to evaluate the feasibility and accuracy of this technique. A retrospective analysis of our experience on 235 SLNB showed that 30(12.7%) had multiple cancer (MC) on final pathologic examination and was considered in relation to the aim of the study.

A further validation of subareolar injection technique for breast sentinel lymph node biopsy.

Background: In this study we performed subdermal injection of (99m)Tc-labeled albumin combined with subareolar (SA) injection of blue dye, and we compared this technique with two techniques previously used in terms of the success of sentinel lymph node (SLN) identification, false-negative (FN) rate, and the overall accuracy and sensitivity of the three procedures. In all patients we performed a complete axillary lymph node dissection.

Methods: From January 1999 to September 2004, a total of 195 patients with localized breast cancer were treated.